by Mark Curtis | Feb 19, 2015
. Welcome to your Update from the Clinic for the month of January. Pluristem and OncoMed reported preliminary efficacy data from early-stage trials, while the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) granted a number of Orphan Drug...
by James Smith | Jan 26, 2015
With contributions from David Brindley . Cell-based treatments are being developed and marketed for a variety of indications: from rare orphan diseases like graft versus host disease (GvHD), to blockbuster conditions like diabetes and cardiovascular disease that...
by Stacey Johnson | Jan 23, 2015
. Signals’ mandate is to bring you, dear reader, blogs about stem cells, commercialization and biomaterials, but lately there hasn’t been much of the latter; therefore, I’ve decided to try to fill that gap. But before you get too excited, I am in no way an expert on...
by Mark Curtis | Jan 13, 2015
. Welcome to your Update from the Clinic for the month of December. bluebird bio’s first four patients are transfusion-free after treatment with its gene therapy Lentiglobin. Fate Therapeutics’ hematopoietic stem cell-modulating technology ProHema seems to be on track...
by Mark Curtis | Jan 7, 2015
. Welcome to your deal review for the month of December. Juno Therapeutics made its leap into the public realm with the largest biotech initial public offering (IPO) in 2014. bluebird Bio announced pricing of a common offering to raise over $200M. Read on to find out...
by Mark Curtis | Dec 23, 2014
. Welcome to your Update from the Clinic for the month of November. NeoStem announced initial positive data from its Phase 2 study in acute myocardial infarction. Neuralstem’s human neural stem cells are shown to have long-term viability following transplant, while...
Comments